Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia

Several studies have compared the molecular responses between e14a2 and e13a2 BCR::ABL1 transcripts in chronic myeloid leukemia (CML) patients treated with front‐line imatinib, but there were very limited studies on nilotinib or dasatinib‐treated patients. We retrospectively analyzed the molecular r...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Yi‐Jiun, Kuo, Ming‐Chung, Chen, Tsai‐Yun, Wang, Ming‐Chung, Yang, Youngsen, Ma, Ming‐Chun, Lin, Tung‐Liang, Lin, Tung‐Huei, Chang, Hung, Teng, Chieh‐Lin Jerry, Hsiao, Pei‐Ching, Chen, Chih‐Cheng, Wang, Po‐Nan, Shih, Lee‐Yung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530867/
https://www.ncbi.nlm.nih.gov/pubmed/35869805
http://dx.doi.org/10.1111/cas.15501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530867/
https://www.ncbi.nlm.nih.gov/pubmed/35869805
http://dx.doi.org/10.1111/cas.15501

Ejemplares similares